AMH Equity Ltd Grows Position in Harvard Bioscience, Inc. $HBIO

AMH Equity Ltd grew its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 3.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,508,703 shares of the medical instruments supplier’s stock after purchasing an additional 121,348 shares during the quarter. Harvard Bioscience makes up approximately 2.0% of AMH Equity Ltd’s portfolio, making the stock its 20th biggest position. AMH Equity Ltd owned 7.94% of Harvard Bioscience worth $1,557,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nuveen LLC purchased a new stake in shares of Harvard Bioscience during the first quarter valued at approximately $79,000. Williams & Novak LLC boosted its stake in shares of Harvard Bioscience by 37.0% during the second quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 28,800 shares during the period. Deutsche Bank AG boosted its stake in shares of Harvard Bioscience by 221.1% during the first quarter. Deutsche Bank AG now owns 75,985 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 52,319 shares during the period. Pasadena Private Wealth LLC boosted its stake in shares of Harvard Bioscience by 23.2% during the second quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 45,872 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Harvard Bioscience during the first quarter valued at approximately $33,000. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Trading Up 41.1%

Shares of Harvard Bioscience stock opened at $0.63 on Friday. The firm has a market capitalization of $28.05 million, a P/E ratio of -0.48 and a beta of 1.52. The business has a fifty day simple moving average of $0.45 and a two-hundred day simple moving average of $0.44. Harvard Bioscience, Inc. has a 12 month low of $0.28 and a 12 month high of $2.82.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, August 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harvard Bioscience in a research note on Wednesday, October 8th. Finally, Benchmark decreased their price target on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating for the company in a research note on Wednesday, September 10th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Harvard Bioscience currently has an average rating of “Hold” and a consensus target price of $2.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.